We found that MYBL2 overexpression is also associated with elevated somatic mutation load in breast cancer cells and tumors as evidenced by the fact that B-Myb is a critical factor for A3B-induced DNA mutation, although we cannot rule out the possibility that B-Myb regulates other DNA-modifying enzymes. This evidence concerns the gene APOBEC3B and breast carcinoma.